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Abstract
In early detection of disease, a single biomarker often has inadequate classification performance,
making it important to identify new biomarkers to combine with the existing marker for improved
performance. A biologically natural method to combine biomarkers is to use logic rules, e.g. the
OR/AND rules. In our motivating example of early detection of pancreatic cancer, the established
biomarker CA19-9 is only present in a subclass of cancer; it is of interest to identify new biomark-
ers present in the other subclasses and declare disease when either marker is positive. While there
has been research on developing biomarker combinations using the OR/AND rules, the inference
regarding the incremental value of the new marker within this framework is lacking and challeng-
ing due to a statistical non-regularity. In this paper, we aim to answer the inferential question of
whether combining the new biomarker achieves better classification performance than using the ex-
isting biomarker alone, based on a nonparametrically estimated OR rule that maximizes the weighted
average of sensitivity and specificity. We propose and compare various procedures for testing the
incremental value of the new biomarker and constructing its confidence interval, using bootstrap,
cross-validation, and a novel fuzzy p-value-based technique. We compare the performance of dif-
ferent methods via extensive simulation studies and apply them to the pancreatic cancer example.
Keywords: Bootstrap; Combining biomarkers; Cross-validation; Fuzzy p-value; Incremental value;
OR/AND rules.
1 Introduction
In early detection of disease, a single biomarker often has inadequate classification performance.
Identifying new biomarkers to combine with established predictors (biomarkers) for improved per-
formance is an important research goal. For classification of binary diseases, examples of com-
mon modeling approaches for combining biomarkers include the likelihood-based logistic regres-
sion model, from which a marker combination score can be derived to subsequently generate a
binary test based on a cutoff value. The use of logistic regression models has been well-studied in
early detection; it yields optimal marker combination when the underlying risk model is correctly
specified, but may otherwise have suboptimal classification performance. Another commonly used
approach in the applied literature for combining markers in a binary test is the use of logic rules
(Etzioni et al., 2003), e.g. the ‘OR/AND’ rules (Feng, 2010), which consider combination rules to
be the set of ‘or-and’ combinations of threshold rules in each biomarker. To declare an individual
as disease-positive, the OR rule requires that either one or the other marker passes its individual
threshold, while the AND rule requires that both markers pass their thresholds. For example, in
early detection of pancreatic cancer, Tang et al. (2015) considered a two-marker panel that declares
disease if either the established biomarker CA19-9 exceeds a threshold OR a new discovered glycan
marker exceeds a threshold. In a prostate cancer screening study, Gann et al. (2002) showed that
the addition of the ratio of free to total PSA (Prostate-Specific Antigen) within a specific total PSA
range with the OR/AND rules could improve both specificity and sensitivity simultaneously relative
to the conventional strategy based on total PSA alone.
Logic combination rules are desirable for combining biomarkers mostly because of their sim-
plicity and interpretability. For example, the OR rule is often preferred due to its biological ap-
peal in detecting cancer, which is typically heterogeneous and composed of different subclasses. If
biomarkers from each subclass can be identified, an OR rule combining these biomarkers is expected
to boost the overall sensitivity without sacrificing much specificity. On the other hand, the AND rule
is considered to be useful when individual biomarkers for combination have very high sensitivity and
low specificity. Our research in this paper is motivated by the development of biomarker combina-
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tions to improve early detection of pancreatic cancer. The current best marker for early detection
of pancreatic cancer is the CA19-9 test, which detects the sialyl-Lewis A (sLeA) glycan. sLeA
levels are not elevated in 25% of pancreatic cancers due to factors such as genetic inability. It is
of interest to discover glycans other than sLeA that are overproduced in some pancreatic cancers
that are low in sLeA. It is hoped that these glycans, when combined with CA19-9 using the OR
rule (i.e. declaring a case if levels of either CA19-9 or the new marker are elevated), can improve
the classification performance over CA19-9 alone (Tang et al., 2015). In other words, an important
question that needs to be addressed here is whether the new biomarker has significant incremental
value when combined with an established biomarker, compared to using the established biomarker
alone. While several authors have conducted statistical research in combination of biomarkers using
the OR/AND rules, the focus in the past has been mainly on algorithm development for finding the
best combination instead of on making inference about the new biomarker’s incremental value. For
example, Baker (2000) proposed a nonparametric multivariate algorithm that extended the idea of
receiver operating characteristic (ROC) cutpoints to multivariate positivity regions in order to find
the optimal ROC curve. Etzioni et al. (2003) considered classifying prostate cancers using OR/AND
rules that combined total PSA with the ratio of free/total PSA; LOGIC regression Ruczinski et al.
(2003) was performed to find the best logic rule that maximizes the cross-validated weighted sum
of sensitivity and specificity. Statistical research to answer the inferential question about the incre-
mental value of a new biomarker, however, is lacking. As we will show next, this is a challenging
problem due to the non-regularity of the incremental estimator under the null hypothesis (i.e. when
the new biomarker has no incremental value over the established biomarker). In this paper, we aim
to fill this gap. We will propose and compare various strategies for making inference regarding a new
biomarker’s incremental value over an established biomarker. We consider a simple OR rule in this
paper for combining the established marker with the new marker, motivated by the pancreatic cancer
example. However, the technique can be generalized to AND rule or OR/AND rule combinations.
This paper is organized as follows: In Section 2, we present an estimator for an OR rule that
maximizes the weighted average of sensitivity and specificity, based on which the incremental value
of the new marker is estimated. We propose different procedures for testing the significance of the
2
incremental value and construct its confidence interval, utilizing the bootstrap, cross-validation, and
a novel fuzzy p-value technique. In Section 3, we conduct extensive simulation studies to compare
performance of different methods. The application of the methods developed to the pancreatic cancer
example is illustrated in Section 4. We make concluding remarks in Section 5.
2 Methodology
Let D be a binary disease outcome, with value 1 for diseased and 0 for non-diseased. Let X
be an established biomarker (predictor) for predicting D and let Y be a new biomarker that we are
interested in evaluating. The objective is to test whether combination of Y with X based on the
OR rule offers any incremental value in classification performance over X alone and to estimate the
incremental value. Suppose a case is declared if either X or Y is elevated, i.e., X > c1 or Y > c2,
for some thresholds c1 and c2. We define sensitivity as Sen (c1, c2) = P (X > c1 OR Y > c2 | D = 1)
and specificity as Spe (c1, c2) = P (X ≤ c1 AND Y ≤ c2 | D = 0). For a test based on the biomarker
X alone, sensitivity and specificity are defined as Sen (c) = P (X > c | D = 1) and Spe (c) =
P (X ≤ c | D = 0), respectively, for some threshold c. To characterize the incremental performance
of the new biomarker Y , we consider the weighted average of sensitivity and specificity as an overall
summary measure of a model’s performance (Han et al., 2011), for pre-specified weight w ∈ (0,1),
for either the model based on X alone or the model based on the combination of X and Y . The
most common special case of the weighted average of sensitivity and specificity is the Youden’s
index (Youden, 1950), which weights a model’s sensitivity and specificity equally. This index will
be adopted in our numerical studies in this paper. In practice, weights for sensitivity/specificity can
be chosen to reflect the relative importance of not missing the detection of a case versus not making
false positive detection of a control, from a cost/benefit perspective. We define the incremental value
of the new marker Y as the increase in the maximum value of the weighted average of sensitivity
and specificity using the OR rule combining X and Y compared with the rule using X alone, i.e.
θ =max
c1,c2
[ωSen (c1, c2) + (1−ω)Spe (c1, c2)]−maxc [ωSen (c) + (1−ω)Spe (c)] , (1)
with some weight ω ∈ (0,1). The incremental value is always nonnegative.
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We note a connection between the maximizer of the weighted average of sensitivity and speci-
ficity and a logic regression risk model (Ruczinski et al., 2003). Specifically, suppose the risk of the
disease conditional on the established biomarker X follows a logic regression model
P (D = 1 | X ) = α0 +α1I (X > c) . (2)
When conditions in Result 1 below are satisfied, the threshold c in (2) will be the one that maximizes
the weighted average of sensitivity and specificity in a binary classification rule based on X alone.
Similarly, suppose the risk of disease conditional on X and Y follows a logic regression model
P (D = 1 | X ,Y ) = β0 + β1I (X > c1 OR Y > c2) . (3)
When conditions in Result 2 below are satisfied, the thresholds c1 and c2 in (3) will be the corre-
sponding thresholds for X and Y that maximize the weighted average of sensitivity and specificity
in an OR rule.
Result 1 For a binary rule based on X that classifies an observation as diseased if X > δ, suppose
the threshold value c∗ is the unique maximizer of the weighted average of sensitivity and specificity,
i.e., c∗ = argmax
δ
[ωSen (δ) + (1−ω)Spe (δ)]. If (2) holds, the CDF of X is not flat in a neigh-
borhood of X , ω α0+α1P(D=1) − (1−ω) 1−α0−α1P(D=0) > 0 and ω −α0P(D=1) + (1−ω) 1−α0P(D=0) > 0, then c∗ equals the
parameter c indexing (2).
Proof:
Assume risk model (2) holds. We can show that for δ ≥ c,
Sen(δ) =
P(X > δ,D = 1)
P(D = 1)
=
∫∞
δ+
P(D = 1|x)dFX (x)
P(D = 1)
=
(α0 +α1)(1− FX (δ))
P(D = 1)
,
and that for δ ≤ c,
Sen(δ) =
P(D = 1)− P(X ≤ δ,D = 1)
P(D = 1)
= 1−
∫ δ
−∞ P(D = 1|x)dFX (x)
P(D = 1)
= 1− α0(1− FX (δ))
P(D = 1)
.
Similarly, Spe(δ) equals 1− (1−α0−α1)(1−FX (δ))P(D=0) for δ ≥ c and equals (1−α0)(1−FX (δ))P(D=0) for δ ≤ c.
Let A(δ) =ωSen (δ) + (1−ω)Spe (δ), then for δ > c,
A(δ)− A(c) =

ω
α0 +α1
P (D = 1)
− (1−ω) 1−α0 −α1
P (D = 0)

[FX (c)− FX (δ)] ;
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and for δ < c,
A(δ)− A(c) =

ω
−α0
P (D = 1)
+ (1−ω) 1−α0
P (D = 0)

[FX (δ)− FX (c)] ,
where FX is the CDF of the biomarker X . Therefore, c∗ = c if ω
α0+α1
P(D=1) − (1−ω) 1−α0−α1P(D=0) > 0 and
ω
−α0
P(D=1) + (1−ω) 1−α0P(D=0) > 0.
Result 2 For an OR rule based on X and Y that classifies an observation as diseased if X > δ1 or
Y > δ2, suppose the threshold value (c
∗
1, c
∗
2) for X and Y is the unique maximizer of the weighted
average of sensitivity and specificity, i.e.,
 
c∗1, c
∗
2

= argmax
δ1,δ2
[ωSen (δ1,δ2)+
(1−ω)Spe (δ1,δ2)]. If condition (3) holds, the CDF of (X ,Y ) is not flat in the neighborhood
of c1, c2, ω
β0+β1
P(D=1) − (1−ω) 1−β0−β1P(D=0) > 0 and ω −β0P(D=1) + (1−ω) 1−β0P(D=0) > 0, then (c∗1, c∗2) equals
parameters (c1, c2) indexing (3).
Proof:
Assume risk model (3) holds, we can derive Sen(δ1,δ2) and Spe(δ1,δ2) for various combina-
tions of δ1 and δ2. For example, for δ1 ≤ c1 and δ2 ≤ c2,
Sen(δ1,δ2) = 1− P(X ≤ δ1 & Y ≤ δ2,D = 1)P(D = 1)
= 1−
∫ δ1
−∞
∫ δ2
−∞β0dFX ,Y (x , y)
P(D = 1)
= 1− β0FX ,Y (δ1,δ2)
P(D = 1)
,
Spe(δ1,δ2) =
P(X ≤ δ1 & Y ≤ δ2,D = 0)
P(D = 0)
=
∫ δ1
−∞
∫ δ2
−∞β0dFX ,Y (x , y)
P(D = 0)
=
β0FX ,Y (δ1,δ2)
P(D = 0)
.
Let B (δ1,δ2) =ωSen (δ1,δ2) + (1−ω)Spe (δ1,δ2). We can show that
for δ1 ≤ c1, δ2 < c2,
B (δ1,δ2)− B (c1, c2) =

ω
−β0
P (D = 1)
+ (1−ω) 1− β0
P (D = 0)

FX ,Y (δ1,δ2)− FX ,Y (c1, c2)

;
for δ1 > c1, δ2 < c2,
B (δ1,δ2)− B (c1, c2) =

ω
−β0
P (D = 1)
+ (1−ω) 1− β0
P (D = 0)

FX ,Y (c1,δ2)− FX ,Y (c1, c2)

+

ω
β0 + β1
P (D = 1)
− (1−ω) 1− β0 − β1
P (D = 0)

FX ,Y (c1,δ2)− FX ,Y (δ1,δ2)

;
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for δ1 ≤ c1, δ2 > c2,
B (δ1,δ2)− B (c1, c2) =

ω
−β0
P (D = 1)
+ (1−ω) 1− β0
P (D = 0)

FX ,Y (δ1, c2)− FX ,Y (c1, c2)

+

ω
β0 + β1
P (D = 1)
− (1−ω) 1− β0 − β1
P (D = 0)

FX ,Y (δ1, c2)− FX ,Y (δ1,δ2)

;
and for δ1 > c1, δ2 > c2,
B (δ1,δ2)− B (c1, c2) =

ω
β0 + β1
P (D = 1)
− (1−ω) 1− β0 − β1
P (D = 0)

FX ,Y (c1, c2)− FX ,Y (δ1,δ2)

,
where FX ,Y is joint CDF of biomarkers X and Y . Therefore, c∗1 = c1, c
∗
2 = c2 if ω
β0+β1
P(D=1) −
(1−ω) 1−β0−β1P(D=0) > 0 and ω −β0P(D=1) + (1−ω) 1−β0P(D=0) > 0.
In general, even when the actual disease risk model conditional on biomarker(s) may not follow
the conditions specified in Results 1 and 2, it is still appealing to identify classification rules based
on X alone or an OR combination of X and Y by maximizing the weighted average of sensitivity and
specificity, given that the weighted average of sensitivity and specificity is a clinically meaningful
operational criterion of practical interest. So is the estimation of the incremental value of Y based
on difference in model performance, as defined in equation (1).
2.1 Inference
2.1.1 Estimation
To estimate the incremental value θ , we consider nonparametric estimators of the classification
rule based on either X alone or combinations of X and Y . In particular, we estimate threshold(s)
in the corresponding rules by maximizing the weighted average of nonparametric estimates of sen-
sitivity and specificity. Let subscripts D and D¯ indicate case and control status, respectively, such
that XD and YD indicate biomarker measurements among cases and X D¯ and YD¯ indicate biomarker
measurements among controls. Let nD and nD¯ be sample sizes for cases and controls, respectively.
We compute cˆ as the maximizer in c of w
∑nD
i=1 I(XDi > c)/nD + (1 − w)
∑nD¯
j=1 I(X D¯ j ≤ c)/nD¯.
Similarly we compute cˆ1 and cˆ2 as the maximizers in c1 and c2 of w
∑nD
i=1 I(XDi > c1 OR YDi >
c2)/nD + (1 − w)∑nD¯j=1 I(X D¯ j ≤ c1 AND YD¯ j ≤ c2)/nD¯. Based on cˆ, cˆ1 and cˆ2, we then estimate θ
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nonparametrically as
θˆ =

w
nD
nD∑
i=1
I(XDi > cˆ1 OR YDi > cˆ2) +
1−w
nD¯
nD¯∑
j=1
I(X D¯ j ≤ cˆ1 AND YD¯ j ≤ cˆ2)

−

w
nD
nD∑
i=1
I(XDi > cˆ) +
1−w
nD¯
nD¯∑
j=1
I(X D¯ j ≤ cˆ)

.
Note however this ‘naïve’ estimator estimates the rule and its performance from the same dataset
and thus is subject to overfitting bias. To reduce overfitting, a K-fold cross-validation method can be
adopted instead. In performing cross-validation, first the dataset is split into K mutually exclusive
and exhaustive subsets stratified on case/control status. Each time, one of the K subsets is used
as the test set and the remaining K − 1 subsets are combined together to form a training set. The
thresholds are estimated based on the training set and then they are used to obtain the incremental
value estimator based on the kth test set, denoted by θˆk. The cross-validated estimator of incremental
value is produced by taking average of the resulting K estimators, i.e.,
θˆCV =
1
K
K∑
k=1
θˆk.
Next we investigate approaches to test the hypothesis that Y has significant incremental value
when combined with X through an OR rule, i.e., to test
H0 : θ = 0 versus H1 : θ > 0,
as well as approaches to construct confidence interval of the incremental value. We will investi-
gate bootstrap-based approaches for inference as well as proposing a novel fuzzy P-value-based
approach.
2.1.2 Bootstrap Approach
A challenge with the test of incremental value in this problem setting is the non-regularity of
the incremental value estimator under the null hypothesis. In other words, the naïve nonparametric
estimator θˆ is not asymptotically normal so the standard testing procedure based on asymptotic
normality of the test statistics is not applicable here. Figure 1 presents numerical examples of
distribution of θˆ for various θ values. When the null hypothesis is true (θ = 0), θˆ is heavily
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right-skewed with a peak at zero. The distribution of θˆ gradually approaches normality as θ moves
away from zero.
A commonly used approach for performing hypothesis tests is to construct bootstrap (Efron and
Tibshirani, 1994) confidence intervals (CI) for an estimand and evaluate whether the CI covers the
parameter value specified in the null hypothesis. Here we investigate different bootstrap methods
to perform the hypothesis test about the incremental value of Y . Both empirical and percentile
bootstrap methods are considered. Suppose we have a data set of size n, from which we draw B
random samples of size n with replacement, stratified on case/control status. Let θˆ and θˆ ∗ be the
nonparametric incremental value estimates based on the original data set and the bootstrap samples,
respectively. The one-sided (1−α)×100% empirical bootstrap confidence intervals are constructed
as

2θˆ − θˆ ∗1−α,∞

, where θˆ ∗1−α denotes the 1−α quantile of θˆ ∗. The one-sided (1−α)×100% per-
centile bootstrap confidence intervals are constructed as

θˆ ∗
α
,∞. The one-sided test for the incre-
mental value being greater than zero can be based on whether the lower bound of the (1−α)×100%
one-sided bootstrap CI is above zero. Percentile bootstrap CI has been widely used in biomarker re-
search for characterizing and comparing biomarker performances. However, its validity requires
symmetry in the distribution of the estimator (Van der Vaart, 1998), which is clearly violated under
the null hypothesis in our problem setting based on θˆ . In contrast, the rationale behind the empirical
bootstrap is to approximate the distribution of θˆ−θ by the distribution of θˆ ∗− θˆ . From Figure 1, the
right tails of the distributions for θˆ and θˆ ∗ agree reasonably well, suggesting the potential of testing
the incremental value based on the lower confidence limit of the one-sided empirical bootstrap CI
based on θˆ . Nonetheless, we emphasize that we do not currently have theory supporting the valid-
ity of the bootstrap under the null, and therefore our simulation will serve as preliminary evidence
for or against its validity. Hereafter we refer to the approaches based on empirical bootstrap CI or
percentile bootstrap CI of θˆ as EB and PB, respectively.
In addition to bootstrap CIs based on the naïve estimate θˆ , we also consider the construction of
Wald-type CIs based on θˆCV , the cross-validated incremental estimate. From Figure 1, the distribu-
tion of the cross-validated estimate θˆCV is approximately normal under both the null and the alterna-
tive hypotheses, suggesting the validity of using Wald method for CI construction, where the cross-
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validated estimate is computed on each bootstrap sample. The one-sided and two-sided (1−α)×
100% Wald CIs are

θˆCV − z1−αSD
 
θˆ ∗CV

,∞ and θˆCV − z1−α/2SD  θˆ ∗CV  , θˆCV + z1−α/2SD  θˆ ∗CV ,
respectively, where z1−α denotes the 1−α quantile of a standard normal random variable, SD
 
θˆ ∗CV

is
the standard deviation of bootstrap cross-validated estimate θˆ ∗CV . Hereafter we refer to the approach
based on Wald CI of θˆ as Wald.CV.
Figure 1: Distributions of θˆ and θˆCV based on 1000 simulated datasets, θˆ ∗ and θˆ ∗CV over 500
bootstrap samples, for θ = 0, 0.01 and 0.05.
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2.1.3 Fuzzy P-value Approach
In this section, we propose a novel test for incremental value of Y that leverages the fact
that n1/2θˆ will converge to zero under the null given some regularity conditions. Let ψ =
max
c1,c2
[ωSen (c1, c2) + (1−ω)Spe (c1, c2)] and φ =maxc [ωSen (c) + (1−ω)Spe (c)]. Under some
regularity conditions, the key of which is that the c maximizingωSen (c)+(1−ω)Spe (c) is unique,
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one can show that the NPMLE φˆ satisfies the following asymptotically linear expansion
φˆ −φ = 1
n
n∑
i=1

ω
I{Di = 1}
P(D = 1)
[I{X i > c∗} − P(X > c∗|D = 1)]
+ (1−ω) I{Di = 0}
P(D = 0)
[I{X i ≤ c∗} − P(X ≤ c∗|D = 0)]

+ oP(n
−1/2), (4)
where above oP(n−1/2) represents a term that converges to zero in probability once multiplied by
n1/2. The term in the sum represents the canonical gradient of the parameter φ (Bickel et al.,
1993). Under the i.i.d. assumption,
p
n
 
φˆ −φ   N 0,σ2
φ

as the sample size goes to infinity,
where σ2
φ
is the efficiency bound for regular and asymptotically linear estimators for φ within the
nonparametric model. Here we have made the simplifying assumption that the data are a sample of
n independent and identically distributed (i.i.d.) observations, so that standard efficiency theory can
be applied. Nonetheless, if a fixed number of cases and controls are sampled, then the dominant term
above breaks into the sum of an empirical mean over cases and an empirical mean over controls, and
the remainder term will remain negligible. Hence, central limit theorem results can be obtained in
that case as well. Under similar regularity conditions, the key of which is that the c1, c2 in the closure
of the support of X ,Y maximizing ωSen (c1, c2) + (1−ω)Spe (c1, c2) are unique,
ψˆ−ψ= 1
n
n∑
i=1

ω
I{Di = 1}
P(D = 1)

I{X i > c∗1 OR Yi > c2} − P(X > c∗1 OR Y > c∗2|D = 1)

+ (1−ω) I{Di = 0}
P(D = 0)

I{X i ≤ c∗1 AND Yi ≤ c2} − P(X ≤ c∗1 AND Y ≤ c∗2|D = 0)

+ oP(n
−1/2). (5)
Hence,
p
n
 
ψˆ−ψ  N 0,σ2
ψ

. Under the assumptions needed for (4) and (5) to hold, the null
hypothesis that θ = 0 implies that c∗2 falls at the upper edge of the support for Y , in the sense that it
is equal to the smallest number c2 such that P(Y > c2) = 0. In this case, the right-hand sides of (4)
and (5) are equivalent up to an oP(n−1/2) term, so that
Under the null: n1/2θˆ = n1/2[θˆ − θ] = n1/2[ψˆ−ψ]− n1/2[φˆ −φ] = oP(1).
Now, using that ψˆ and φˆ are consistent estimators, we also have that
Under a fixed alternative: n1/2θˆ diverges in probability,
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i.e., for any fixed t > 0, P(n1/2θˆ > t)→ 1 as n→∞.
We now use these facts to introduce a fuzzy p-value. Let F denote a cumulative distribution
function for a continuous random variable on R. By the above two facts, if Z is a random variable
with cumulative distribution function F , under the null p(Z)≡ F(Z−n1/2θˆ ) converges to a standard
uniform random variable, whereas, under a fixed alternative, p(Z) converges in probability to 1.
Note that p(Z) is a valid fuzzy p-value according to the definition given in Geyer and Meeden
(2005). To generate a concrete decision, one could sample Z from F and reject if p(Z) > α. Under
the null hypothesis, the null will reject with probability approaching α. In our simulation, we use
θˆCV in computation of the fuzzy p-value to minimize over-fitting bias in small sample size; we let
F be equal to the CDF of the normal distribution N

0, σˆ2
ψ

, where the estimate σˆ2
ψ
of the variance
σ2
ψ
is estimated via the bootstrap.
3 Simulation Study
In this section, we conduct simulation studies to compare the performance of the methods de-
scribed in Section 2 for testing and making inference about a new biomarker’s incremental value.
Here we consider equally weighted sensitivity and specificity as the classification performance mea-
sure and define φ and ψ as the optimal average sensitivity and specificity based on an established
marker alone or based on its combination with a new marker with an OR rule. The incremental value
θ is then defined as the difference between ψ and φ.
Let D be a binary disease outcome. Let X and Y be two biomarkers that are independently
distributed; each follows the standard normal distribution. We consider two scenarios where
the underlying true risk model is (1) a logic model for the risk of D conditional on X and Y :
P (D = 1 | X ,Y ) = β0 + β1I (X > c1 OR Y > c2) with thresholds c1, c2 and parameters β0, β1. ,
and (2) a logistic risk model logi t (P (D = 1 | X ,Y )) = log(1/9) + β∗1X + β∗2Y , yet investigators
have adopted the simple OR rule to combine X and Y . In both scenarios, we set disease prevalence
P (D = 1) = 0.1 with appropriate selection of c1, c2, β0, β1, β∗1 and β
∗
2 . For the logic model, the true
incremental value of Y is 0 when c2 =∞, otherwise it is greater than 0. We choose two different
values of the threshold for biomarker X , c1 = 0 and 0.842, which correspond to the 50th and 80th
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percentiles of the standard normal distribution, respectively. In the following, we select different
values of β0, β1 or β∗1 , β
∗
2 to achieve a wide variety of classification performance based on X alone
(φ) or based on the OR combination of X and Y (ψ). Here we consider the scenario where clas-
sification performance of the established biomarker X is not very weak (φ ≥ 0.6), which is likely
to be true in practice. A range of incremental values {θ = 0, 0.05, or 0.1} are considered in our
simulation studies.
We consider case/control samples with equal numbers of cases and controls nD = nD¯ = 100, 250
or 500 randomly sampled from the population, based on which we compute the naïve performance
estimate θˆ and the cross-validated estimate θˆCV based on 10-fold cross-validation. For each setting,
we evaluate bias of θˆ and θˆCV . We compare four different methods to perform the one-sided test for
incremental value with respect to type I error rate and power: i) EB: the method based on empirical
bootstrap CI using θˆ , ii) PB: the method based on percentile bootstrap CI using θˆ , iii) Wald.CV,
Wald test using θˆCV , and iv) the fuzzy p-value approach. In addition, we examine coverage of
95% two-sided CI of incremental value using the Wald.CV method. In each setting, 1000 Monte-
Carlo simulations are conducted with 1000 bootstrap replicates constructed stratified on case/control
status. The simulation results for various scenarios and sampling size at each fixed θ are summarized
in Tables 1, 2, and 3. Corresponding results under local alternative where θ ∝ n−1/2D are presented
in the appendix (Table 4).
From Tables 1 and Table 4 (appendix), under both correctly specified and mis-specified underly-
ing models, we see that the naïve estimator tends to overestimate the new biomarker’s performance
when the true incremental value is small (e.g. θ ≤ 0.05); the overestimation issue becomes less se-
vere as sample size increases as well as for settings with better performance of X alone (i.e. settings
with larger φ value). Using cross-validation in general corrects this overestimation problem and can
lead to small attenuation in some settings.
From Table 2, when the null hypothesis is true, the test based on PB often has inflated type I error,
whereas the corresponding test based on EB typically has type I error rate close to or smaller than
the nominal level (e.g. when biomarker X itself has good performance). Wald.CV based on cross-
validated θ estimate controls type I error, while it is often more conservative than EB. The fuzzy
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p-value method works very well with type I error fairly close to the nominal level for all settings.
When the alternative hypothesis is true, the test based on EB in general has better or comparable
power compared to other tests; the performance of Wald.CV and the fuzzy p-value method are more
or less comparable to each other and their relative performance varies across settings.
From Tables 3 and Table 4 (appendix), for the purpose of constructing two-sided CI for the
incremental value, the Wald.CV approach is satisfactory for both underlying models. It clearly
shows that the Wald.CV two-sided CIs have coverage either close to or slightly larger than the
nominal level. Under the mis-specified model and alternative hypothesis, although the two-sided
CIs can have slight undercoverage for the smaller sample size, its coverage approaches the nominal
level as when the sample size is large enough, i.e., nD = nD¯ = 500.
Overall, we observe a similar pattern on performance comparison among different approaches
under the (correctly specified) logic and (mis-specified) logistic risk models. For testing the sig-
nificant incremental value of a new biomarker, the one-sided test based on empirical bootstrap CI
is recommended; the fuzzy p-value approach is also desirable, given its theoretical foundation and
reasonable performance. For making inference about the uncertainty of θ estimator, the Wald CI
based on the cross-validated estimator is desired for constructing two-sided CI about θ .
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Table 1: Naïve and cross-validated (CV) estimates of incremental value and corresponding standard
deviation (SD) in the parenthesis based on 1000 Monte Carlo simulations under different underly-
ing models and scenarios. φ indicates the performance of biomarker X alone and θ indicates the
incremental value.
Correctly specified model (Logic model)
c2 c1 θ φ β0 β1 Estimate (SD) CV Estimate (SD)
nD = nD¯ nD = nD¯
100 250 500 100 250 500
∞ 0 0 0.6 0.064 0.072 0.008 0.003 0.004 -0.012 -0.006 -0.005
(0.010) (0.004) (0.004) (0.025) (0.010) (0.011)
∞ 0 0 0.7 0.028 0.144 0.002 0.001 0.000 -0.008 -0.003 -0.002
(0.004) (0.001) (0.001) (0.010) (0.003) (0.002)
∞ 0.84 0 0.6 0.078 0.113 0.012 0.005 0.003 -0.009 -0.005 -0.003
(0.005) (0.006) (0.003) (0.028) (0.012) (0.007)
∞ 0.84 0 0.7 0.055 0.225 0.005 0.002 0.001 -0.010 -0.004 -0.002
(0.007) (0.003) (0.001) (0.014) (0.006) (0.003)
1.15 0.84 0.05 0.6 0.061 0.129 0.054 0.051 0.051 0.040 0.047 0.048
(0.022) (0.015) (0.011) (0.037) (0.021) (0.013)
0.67 0.84 0.1 0.6 0.04 0.15 0.099 0.099 0.100 0.096 0.098 0.100
(0.031) (0.02) (0.014) (0.045) (0.025) (0.016)
1.53 0.84 0.05 0.7 0.04 0.24 0.053 0.051 0.051 0.044 0.048 0.049
(0.019) (0.012) (0.009) (0.027) (0.014) (0.010)
1.15 0.84 0.1 0.7 0.023 0.257 0.099 0.100 0.100 0.095 0.099 0.099
(0.026) (0.016) (0.012) (0.031) (0.018) (0.012)
Mis-specified model (Logistic model)
θ φ β∗1 β
∗
2 Estimate (SD) CV Estimate (SD)
nD = nD¯ nD = nD¯
100 250 100 250 100 250
0 0.6 0.45 0 0.009 0.004 0.002 -0.011 -0.006 -0.003
(0.011) (0.004) (0.003) (0.027) (0.013) (0.007)
0 0.7 1.1 0 0.003 0.001 0.001 -0.008 -0.004 -0.002
(0.006) (0.002) (0.001) (0.015) (0.007) (0.003)
0.05 0.6 0.5 0.7 0.065 0.058 0.055 0.044 0.046 0.047
(0.031) (0.021) (0.016) (0.054) (0.035) (0.024)
0.1 0.6 0.5 1.05 0.108 0.106 0.104 0.093 0.099 0.100
(0.035) (0.025) (0.017) (0.057) (0.037) (0.024)
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Table 2: Type I error rate and power of one-sided test from the empirical bootstrap (EB), percentile
bootstrap (PB), Wald using cross-validation (Wald.CV), and fuzzy p-value methods, under different
underlying models and scenarios. φ indicates the performance of biomarker X alone and θ indicates
the incremental value.
c1 θ φ nD = nD¯ EB PB Wald.CV Fuzzy p-value
Correctly specified model (Logic model)
Type I error rate
0 0 0.6 100 0.015 0.132 0.006 0.056
250 0.007 0.135 0.003 0.034
500 0.023 0.344 0.008 0.055
0.7 100 0.001 0.009 0.001 0.038
250 0.005 0.006 0.001 0.042
500 0.003 0.011 0.001 0.047
0.84 0.6 100 0.033 0.229 0.011 0.073
250 0.015 0.256 0.002 0.042
500 0.018 0.277 0.004 0.036
0.7 100 0.013 0.077 0.004 0.043
250 0.012 0.087 0.000 0.041
500 0.006 0.078 0.001 0.042
Power
0.05 0.6 100 0.593 0.905 0.255 0.426
250 0.945 0.996 0.710 0.690
500 0.998 1.000 0.969 0.889
0.1 100 0.916 0.988 0.713 0.836
250 1.000 1.000 0.991 0.984
500 1.000 1.000 1.000 1.000
0.05 0.7 100 0.801 0.942 0.499 0.462
250 0.990 0.999 0.949 0.772
500 1.000 1.000 0.997 0.945
0.1 100 0.991 0.997 0.908 0.890
250 1.000 1.000 1.000 0.995
500 1.000 1.000 1.000 1.000
Mis-specified model (Logistic model)
Type I error rate
NA 0 0.6 100 0.019 0.144 0.009 0.069
250 0.021 0.144 0.011 0.057
500 0.008 0.167 0.008 0.041
0.7 100 0.008 0.026 0.005 0.048
250 0.007 0.025 0.006 0.041
500 0.013 0.031 0.004 0.044
Power
0.05 0.6 100 0.512 0.935 0.212 0.466
250 0.755 0.999 0.382 0.647
500 0.924 1.000 0.627 0.812
0.1 100 0.870 0.996 0.519 0.796
250 0.990 1.000 0.871 0.968
500 1.000 1.000 0.991 0.996
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Table 3: Coverage of 95% two-sided confidence interval (CI) and corresponding length in the paren-
thesis using Wald with cross-validation method, under different underlying models and scenarios.
φ indicates the performance of biomarker X alone and θ indicates the incremental value.
c1 θ φ Coverage (Length) of two-sided 95% CI
nD = nD¯
100 250 500
Correctly specified model (Logic model)
0 0 0.6 98.3% (0.117) 99.9% (0.053) 97.8% (0.051)
0.7 98.0% (0.056) 96.8% (0.019) 95.9% (0.008)
0.842 0.6 98.5% (0.123) 98.8% (0.060) 98.2% (0.034)
0.7 97.3% (0.017) 97.9% (0.030) 97.8% (0.015)
0.05 0.6 94.3% (0.154) 96.0% (0.089) 96.5% (0.056)
0.1 0.6 95.4% (0.175) 95.7% (0.100) 96.9% (0.065)
0.05 0.7 93.8% (0.108) 96.4% (0.060) 95.5% (0.039)
0.1 0.7 95.3% (0.128) 95.6% (0.074) 95.7% (0.049)
Mis-specified model (Logistic model)
NA 0 0.6 98.4% (0.123) 97.9% (0.063) 98.0% (0.035)
0 0.7 97.4% (0.072) 97.7% (0.032) 98.6% (0.017)
0.05 0.6 93.7% (0.202) 92.9% (0.132) 94.2% (0.094)
0.1 0.6 92.9% (0.215) 93.2% (0.137) 95.1% (0.097)
4 Pancreatic Cancer Study
In this section, we apply the proposed methods to a real data example from a pancreatic cancer
study for identifying biomarkers for early detection of pancreatic cancer. In this study, plasma sam-
ples were collected from nD = 109 patients with pancreatic cancer and nD¯ = 91 healthy individuals
for biomarker measurement (Tang et al., 2015). The sialyl-Lewis A (sLeA) glycan, on which the
CA19-9 assay is based, is currently the only established biomarker for pancreatic cancer detection.
However, its performance for early detection of pancreatic cancer is not satisfactory given that it
is not evaluated in about 25% of pancreatic cancers. Tang et al. (2015) found that sialyl-Lewis X
(sLeX), a structural isomer of sLeA, was elevated in the plasma of 14-19% of patients with low
sLeA and thus a biomarker panel combining sLeA and sLeX can potentially be useful in the clinical
detection of pancreatic cancer. In this study, the estimated optimal average sensitivity and speci-
ficity based on sLeA alone is 0.683 (0.636 after cross-validation). Here, we estimate the incremental
value of sLeX when combined with sLeA using an OR rule and test the hypothesis that a strategy
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combining the two biomarkers performs better than using the sLeA biomarker alone. The estimated
naïve and cross-validated incremental value of sLeX is 0.079 and 0.062, respectively. We apply the
EB, PB, and Wald.CV methods to construct one-sided confidence intervals for the incremental value
of sLeX. We also apply the fuzzy p-value approach to the data and compute the average rejection
rate over 1000 random draws. In addition, the two-sided CI based on Wald.CV is constructed.
When using the original data set, the one-sided bootstrap CIs based on EB and PB provide
strong evidence against the null hypothesis while the Wald.CV method fails to do so, which is not
surprising given that EB and PB have been shown to be more powerful compared to Wald.CV. The
fuzzy p-value approach rejects the null hypothesis with probability 0.67. The two-sided CI derived
using Wald.CV is [−0.030,0.153].
Moreover, to investigate the impact of increased sample size, we generate a larger dataset by
randomly drawing 200 cases and 200 controls with replacement from the original data and apply
our proposed methods. With the larger sample sizes, CIs based on EB, PB, and Wald.CV all have
lower limits above zero, providing strong evidence that adding sLeX yields significantly better per-
formance compared to using sLeA alone. The fuzzy p-value approach rejects the null hypothesis
with probability 1. The Wald.CV two-sided CI turns out to be [0.066,0.164].
5 Concluding Remarks
In this paper, we considered an inference problem about the incremental value of a new
biomarker when combined with an established biomarker using an OR rule, motivated by the exam-
ple in early detection of pancreatic cancer, where the standard biomarker CA19-9 is only elevated
in a subclass of cancer cases. Thus, identifying a new biomarker that is present in the other sub-
classes to combine with CA19-9 is of primary interest. We considered a nonparametric estimator of
incremental value of the new biomarker, based on an estimator of the OR rule that maximizes the
weighted average of sensitivity and specificity. We proposed different procedures based on boot-
strap, cross-validation and a novel fuzzy p-value approaches, to test and make inference about a
new biomarker’s incremental value. Through extensive numerical studies, we found that the hy-
pothesis test based on one-sided empirical bootstrap CI has satisfactory performance in terms of
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well-controlled type I error rate and decent power for declaring the usefulness of the new marker,
while the popular percentile bootstrap CI should be avoided due to its inflated type I error rate.
When it is of interest to provide uncertainty about the estimated incremental value, we found that
two-sided Wald-type CI based on cross-validated estimates of incremental value performs very well
with the coverage closed to the nominal level. The novel fuzzy p-value method we proposed for test-
ing the incremental value also has satisfactory performance. Moreover, the fuzzy p-value method
can be particularly appealing as a testing procedure given its theoretical foundation and its potential
to be extended to other biomarker testing problems when non-regularity is an issue. Importantly, our
findings are based not only on settings where the true risk model conditional on biomarkers follows
a logic model with an OR combination, but also on settings where the logic risk model does not hold
but the OR rule is used as a practical way to combine biomarkers for simplicity and interpretability.
Our findings provide valuable guidance on selecting appropriate methods for testing and making
inference about the incremental value of a new biomarker.
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Table 4: Naïve and cross-validated (CV) estimates of incremental value with corresponding stan-
dard deviation (SD) in the parenthesis, power of one-sided test from the empirical bootstrap (EB),
percentile bootstrap (PB), Wald using cross-validation (Wald.CV), and fuzzy p-value methods, and
coverage of 95% two-sided confidence interval (CI) with corresponding length in the parenthesis
using Wald.CV method, under the local alternative θ = 0.05
Ç
100
nD
, or 0.1
Ç
100
nD
, based on 1000
Monte Carlo simulations. φ indicates the performance of biomarker X alone and θ indicates the
incremental value.
φ θ nD Estimate CV Estimate Power Coverage
(SD) (SD) (Length)
EB PB Wald.CV Fuzzy of two-sided
p-value 95% CI
0.6 0.05 100 0.054 0.040 0.593 0.905 0.255 0.426 94.30%
(0.022) (0.037) (0.154)
0.03 250 0.034 0.027 0.773 0.985 0.366 0.434 95.00%
(0.012) (0.019) (0.080)
0.02 500 0.024 0.019 0.882 0.993 0.520 0.421 96.20%
(0.007) (0.011) (0.047)
0.1 100 0.099 0.096 0.916 0.988 0.713 0.836 95.40%
(0.031) (0.045) (0.175)
0.06 250 0.064 0.062 0.979 0.999 0.862 0.847 95.40%
(0.017) (0.023) (0.093)
0.04 500 0.046 0.043 0.994 1.000 0.933 0.837 96.30%
(0.010) (0.013) (0.055)
0.7 0.05 100 0.053 0.044 0.801 0.942 0.499 0.462 93.80%
(0.019) (0.027) (0.108)
0.03 250 0.033 0.028 0.914 0.992 0.705 0.445 94.60%
(0.010) (0.013) (0.052)
0.02 500 0.023 0.020 0.976 1.000 0.881 0.461 95.20%
(0.006) (0.007) (0.030)
0.1 100 0.099 0.095 0.991 0.997 0.908 0.890 95.30%
(0.026) (0.031) (0.128)
0.06 250 0.064 0.061 0.999 1.000 0.990 0.890 95.10%
(0.014) (0.016) (0.065)
0.04 500 0.045 0.043 1.000 1.000 0.999 0.898 95.10%
(0.009) (0.009) (0.038)
20
